ÂÜÀòÂÒÂ×

Alain Curaudeau has 30-years of international experience in the United States, Canada and Europe, including more than 15 years in leadership positions in large pharmaceutical organizations (Sanofi) and biotechnology companies (QLT Inc.). He held senior roles in a diverse array of activities including corporate and portfolio management, strategic planning, mergers and acquisitions, in/out-licensing, drug development and alliance management. Recently, as the Head of Oncology Strategy and Portfolio management, at Sanofi, he oversaw activities related to business development (search and evaluation) and alliance management. Alain has held key roles in the development of several drugs including Taxotere, Visudyne and Lovenox, heading the Lovenox Development Unit.

Alain is a graduate of the University of Paris XI (Docteur en Pharmacie) and is certified in toxicology and pharmacokinetics from the same university, as well as in toxicological pathology from the National Veterinary School of Toulouse. Alain has also trained at the Wharton School of Business (executive development program; finance).